Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of Efinopegdutide in Obesity
NCT03586843Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efinopegdutide in obesity (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration, Area Under the Serum Concentration Time Curve and 1 more. Started Jun 2018; status: completed.
02
Drugs
efinopegdutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03586843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586843.